Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
UK Starting Salaries See Strongest Growth in 18 Months as Hiring Sentiment Improves 
Tabletop particle accelerator could transform medicine and materials science 
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility 
NASA and SpaceX Target Crew-11 Undocking From ISS Amid Medical Concern 
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Neuralink Expands Brain Implant Trials with 12 Global Patients 
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Trump’s Inflation Claims Clash With Voters’ Cost-of-Living Reality 
The University of Chicago’s Pritzker School of Molecular Engineering has designed a method to keep a promising cancer drug from wreaking havoc until it reaches a tumor.
As many cancer drugs often attack both healthy cells and tumor cells, causing a plethora of side effects, the drug was engineered to attack only tumor cells and spare the rest of the body.
Immunotherapies, which aid the immune system in identifying and attacking cancer cells, are no exception. Though they have helped countless patients live longer lives, they only work on a small percentage of patients. According to one study, only about 30 percent of breast cancer patients respond to one of the most common types of immunotherapy.
Cytokines are proteins that influence how the immune system reacts to danger. They do this in part by activating killer T cells, which are white blood cells capable of attacking cancer cells. Cytokines hold great promise as cancer treatments because they can train the immune system to kill tumors.
Interleukin-12, or IL-12, is one such cytokine that has yet to be approved by the FDA as a cancer treatment due to serious side effects like liver damage. This is partly due to the fact that IL-12 instructs immune cells to produce a large number of inflammatory molecules that can harm the body.
The researchers used one of the primary distinctions between healthy and malignant tissue, which is an overabundance of growth-promoting enzymes in tumors, to generate a safer version of IL-12. Because cancer cells multiply so quickly, they overproduce enzymes that allow them to infiltrate neighboring healthy tissue and spread to other regions of the body. Healthy cells develop considerably more slowly and produce far fewer of these enzymes.
In light of this, the researchers "masked" IL-12 with a cap that covers the region of the molecule that typically links to immune cells to activate them. The cap is only removed when it comes into touch with enzymes located around tumors. When these enzymes sever the cap, IL-12 is triggered, causing neighboring killer T cells to assault the tumor.
When these disguised IL-12 molecules were administered to both healthy and tumor tissue supplied by melanoma and breast cancer patients, the results revealed that only the tumor samples were able to remove the cap. This suggested that disguised IL-12 may possibly stimulate a powerful immune response against tumors while causing no harm to healthy organs.
